Among COVID-19 vaccine research reports submitted to the World Health Organization (WHO), 10 of them are tested on human bodies. Remdesivir is one of the most promising medicines. It is made by Gilead Sciences, the American pharmaceutical company that developed Tamiflu, a medicine for influenza. The Food and Drug Administration (FDA) granted remdesivir emergency use on May 1st as it can reduce the treatment period of patients with severe COVID-19 in its clinical demonstrations, and it will be sold starting from June. However, remdesivir has not been proven to be 100% safe. Some patients have shown several side effects like diarrhea, rashes, kidney damage, and even death during testing. On May 5th, Gilead Sciences announced that it is examining ways of giving authority to pharmaceutical companies and chemical companies to produce remdesivir in other countries and building consortiums with other manufacturing firms to produce it sufficiently. Also, Moderna, the American biotechnology company, came up with promising news, claiming that it created antibodies in all 45 participants in clinic tests on May 18th. It started to conduct a second level clinic tests on May 29th and will start a third level clinic tests in July. Jerome Kim, the Director General of International Vaccine Institute (IVI), said as many research projects are going on, time spent on the development of the vaccine can be shortened though it is still difficult to develop a vaccine with time constraints and budget problems.